Fitnet delivers a personal fitness experience to mobile combining biometric sensors, fitness coaching, and online workout buddies. Its unique technological approach converts a mobile webcam into a biometric sensor capable of scoring an individual while they work out with a human trainer. The Fitnet application is used in over 190 countries and its clients have collectively burned over 10 million calories since the launch on January 1, 2014.
Heyo, Inc. specializes in providing tools for businesses to create mobile-optimized marketing campaigns across various platforms, including social media and web. Founded in 2010 and based in Blacksburg, Virginia, the company offers a range of products such as customizable templates, promotions, and drag-and-drop builders to facilitate the creation of Facebook contests, sweepstakes, and landing pages. By enabling businesses to design engaging Facebook fan pages and campaigns, Heyo helps enhance customer interaction and drive traffic, leads, and sales. With a focus on mobile accessibility, Heyo also offers solutions that allow businesses to communicate messages directly to customers' mobile devices. As of 2016, Heyo operates as a subsidiary of Votigo, Inc.
Transgenomic, Inc. (Transgenomic) provides products for the purification and analysis of nucleic acids used in the life sciences industry for research focused on molecular genetics and diagnostics. The Company also provides genetic variation analytical services to the medical research, clinical and pharmaceutical markets. Its products and services are categorized as Instrument Related Business and Laboratory Services. It has sold its products to customers in over 50 countries. Customers include numerous academic and medical institutions in the United States and abroad. In addition, its customers also include number of pharmaceutical, biotech and commercial companies both in the United States and abroad. In December 2010, the Company acquired Clinical Data, Inc.'s diagnostic business. ransgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.
AmpliPhi Biosciences is a biopharmaceutical company dedicated to developing bacteriophage-based therapies for the treatment of bacterial infections, particularly those caused by drug-resistant strains prevalent in hospital settings. Utilizing an internally generated pipeline of naturally occurring viruses, AmpliPhi employs a drug development and manufacturing platform that facilitates the rapid creation and production of various phage-based treatments. The company's initial focus is on addressing acute and chronic infections in the lung, sinus, and gastrointestinal areas. AmpliPhi operates in multiple locations, including Richmond, Virginia, Colworth Science Park in the United Kingdom, and near Sydney, Australia.
Soligenix, Inc. is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey, dedicated to developing and commercializing products aimed at treating rare diseases and addressing biodefense needs. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. In the BioTherapeutics segment, Soligenix is advancing SGX301, a photodynamic therapy for cutaneous T-cell lymphoma, and SGX942, an innate defense regulator for oral mucositis in head and neck cancer, both in Phase 3 clinical trials. Additionally, it is developing a proprietary oral formulation of beclomethasone for severe gastrointestinal disorders, currently in Phase 1/2 trials. The Public Health Solutions segment focuses on developing a ricin toxin vaccine candidate, RiVax, which has completed early clinical trials, and SGX943, a therapeutic for antibiotic-resistant infections, currently in pre-clinical development. The company was previously known as DOR BioPharma, Inc. before rebranding to Soligenix in 2009.
Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Synchrony Financial is a prominent consumer financial services company based in the United States, specializing in providing a variety of financing programs and banking products tailored for diverse industries such as retail, healthcare, and automotive. The company is recognized as the largest provider of private label credit cards in the country, offering products that include private label credit cards, dual cards, and general-purpose co-branded credit cards, along with promotional financing options for consumer purchases and elective healthcare services. Synchrony also provides deposit products like certificates of deposit and individual retirement accounts, catering to both retail and commercial customers. Its credit products are marketed through partnerships with national and regional retailers, as well as healthcare service providers, utilizing various channels including digital platforms. Founded in 2003 and headquartered in Stamford, Connecticut, Synchrony Financial has established a significant presence in consumer financing, leveraging its expertise to support businesses and enhance customer experiences.
Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.
Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics.
Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
LevelVision designs and deploys video display technologies, and provides marketing solutions to the place-based, ambient, and out-of-home marketing industries.
Synchrony Financial is a prominent consumer financial services company based in the United States, specializing in providing a variety of financing programs and banking products tailored for diverse industries such as retail, healthcare, and automotive. The company is recognized as the largest provider of private label credit cards in the country, offering products that include private label credit cards, dual cards, and general-purpose co-branded credit cards, along with promotional financing options for consumer purchases and elective healthcare services. Synchrony also provides deposit products like certificates of deposit and individual retirement accounts, catering to both retail and commercial customers. Its credit products are marketed through partnerships with national and regional retailers, as well as healthcare service providers, utilizing various channels including digital platforms. Founded in 2003 and headquartered in Stamford, Connecticut, Synchrony Financial has established a significant presence in consumer financing, leveraging its expertise to support businesses and enhance customer experiences.
Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Diffusion Pharmaceuticals, LLC, a clinical-stage drug-discovery and development company, engages in the commercialization of small-molecule therapeutics to treat serious or life-threatening medical conditions by increasing the amount of oxygen to hypoxic tissues. Its products include trans sodium crocetinate and trans bipolar carotenoids molecules, which are used to treat life-threatening conditions, such as trauma, cancer, stroke, cardiovascular diseases, respiratory disorders, peripheral vascular and arterial diseases, and various other conditions. Diffusion Pharmaceuticals, LLC was founded in 2001 and is based in Charlottesville, Virginia.